Shenchang Medical Completes Hundreds of Millions RMB Series A Financing to Accelerate the Building of a New Landscape in China's High-End Neuroscience Medical Sector

Recently, NEULIVE MEDICAL (hereinafter referred to as"NEULIVE MEDICAL" announced the completion of its Series A financing round, which was led by LYFE Capital and Suzhou Chenzhide Investment Partnership(L.P.), with a financing scale reaching hundreds of millions of RMB. In the current situation where China's high-end neuroscientific medical devices are long dominated by imported equipment, NEULIVE MEDICAL has caused a sensation in the industry and gained significant recognition and affirmation due to its leading technological level and outstanding non-homogenized innovation capabilities. This financing round also garnered the favor of several top-tier capital firms, achieving an unprecedented scale.

NEULIVE MEDICAL is a medical technology company based in China with a global presence. The company has a comprehensive layout in the six major disease areas of neuroscience, focusing on the two main lines of neurointervention and neuromodulation. It is committed to providing patients with comprehensive and high-quality overall solutions for neurointervention and neuromodulation. The treated diseases cover hemorrhagic and ischemic stroke, pain, epilepsy, Parkinson's disease, obsessive-compulsive disorder, and more.

Over the past 30 years, the incidence of neurological diseases in China has continued to increase. The number of stroke patients has reached 13 million, and the mortality and disability rate exceeds that of cardiovascular diseases, malignant tumors, and others, ranking first among various diseases. Moreover, the number of patients with neurological disorders such as pain, epilepsy, Parkinson's disease, and obsessive-compulsive disorder has reached hundreds of millions, seriously affecting the quality of life of patients. However, the current treatment methods in China cannot meet the enormous clinical demand domestically, and new interventional therapies are urgently needed for development and innovation by medical experts.

From the perspective of participants, China's high-end medical devices in the field of neuroscience have broad potential for development. The number of domestic competitors is increasing, but as competition becomes increasingly fierce, there is a serious trend of product homogenization in the neurointerventional field, with only a few products addressing clinical pain points. In contrast, the neuromodulation field in China remains largely untapped due to the high difficulty of industrial production and significant technical barriers, resulting in very few companies venturing into this area, leaving the industry still a blue ocean.

Among many Chinese enterprises, NEULIVE MEDICAL has managed to break through the competition and establish a highly competitive proprietary product system, relying on its top-notch in-house R&D capabilities and globally leading core technologies and craftsmanship. Since its establishment, the company has made comprehensive arrangements and developments in multiple areas within the fields of neurointervention and neuromodulation. With unique innovative products, it has avoided the trap of homogenized competition. Several products have entered clinical trials, and a few are expected to achieve global leadership, filling the gap in China-produced solutions. NEULIVE MEDICAL is the first Chinese enterprise to fully cover the neuroscience sector and truly achieve breakthroughs in technical barriers.

The CEO of NEULIVE MEDICAL stated, "Having底层技术能力 is the driving force behind NEULIVE's rapid and stable development, and it is also the key to making our products stand out in the market." He also emphasized, "Competing in the neuroscience赛道 is like thousands of soldiers crossing a narrow bridge—failure to advance means falling behind. In the future, we will fully leverage our independent innovation advantages, continuously enrich our product portfolio, accelerate product iteration, and persistently explore areas where China has yet to make breakthroughs. We aim to develop more products that meet market demands and address patients' pain points, paving the way for a new era of high-end medical devices in China's neuroscientific field!"

Currently, whether in the field of neurointervention or neuromodulation, China is still in the early stage of development, and imported products continue to dominate the market. The vast undeveloped market in China has attracted significant capital investment, while innovative companies are also dedicating themselves wholeheartedly to promoting the high-quality development of advanced medical devices in China's neuroscience sector.

In the field of neurointervention, NEULIVE MEDICAL is the only domestic company in the industry that possesses both manual braiding and advanced mechanical braiding capabilities, with full-line independent research and development. Currently, NEULIVE MEDICAL has innovatively developed products for hemorrhagic stroke, such as flow diverter stents, assistive stents, and intrasaccular occlusion devices, as well as ischemic stroke and access products like aspiration devices, catheters, and guidewires. Several of these products are globally leading in technology, and many have entered clinical trials. In terms of neuromodulation, NEULIVE MEDICAL demonstrates strong original research capabilities, with a team that masters globally leading core technologies and processes. The company has established R&D bases in both China and the U.S., creating a dual-engine product development structure. The current development of products such as Golden Crown and Golden Needle is set to revolutionize traditional therapies, and upon their release, they will reshape the landscape of China's neuromodulation field.

The research and development of high-end medical devices in China's neuroscience field is in full swing. To remain invincible in a market filled with top competitors, innovation has always been the constant theme. NEULIVE MEDICAL consistently regards innovation as the soul of the enterprise. The company boasts a founding and R&D team that holds authoritative status in China’s neuroscience sector, with decades of average experience in innovative R&D for related products. Additionally, the company possesses top industry resources from production, academia, and research both domestically and internationally. Its unparalleled R&D and innovation capabilities are bound to establish NEULIVE MEDICAL as a global brand representing China's indigenous research and development strengths.

NEULIVE MEDICAL's CEO expressed his vision for the company’s future development: "NEULIVE MEDICAL adheres to a sense of responsibility for human health and a mission of innovative breakthroughs, continuously revolutionizing medical solutions. We firmly believe that only by perfecting our products and technology can we ensure the long-term success of the company and its spirit. Through continuous creativity, we aim to open up a new landscape for high-end medical devices in China’s neuroscience field, driving a complete transformation of China’s medical technology. We hope to help tens of thousands of patients regain their health and start anew by using NEULIVE products."

A thousand sails vie, and the brave prevail. It is believed that NEULIVE MEDICAL will soon seize the "bull by the horns" in innovation within China's neuroscience field, making the first strategic move in the development of advanced neurointerventional and neuromodulation medical devices. We also look forward to its continuous expansion of application scenarios for neuromodulation and interventional products, as well as pioneering new pathways for patient healthcare solutions, creating a brand-new future for China's neuroscience!

Hu Xuyu, Managing Partner of Ji Feng Capital, stated: "There are significant unmet clinical needs and a large patient population in the fields of neurointervention and neuromodulation, with the market maintaining rapid growth. NEULIVE MEDICAL has a top-tier R&D team and continuous innovation capabilities, leading in product iteration and innovation across multiple therapeutic device areas such as aneurysms and neuromodulation. We are highly optimistic about the company’s neuroscience platform strategy and hope that its high-quality products can be launched soon to bring benefits to patients."

Chenzhide Capital stated: "Medical devices for the treatment of neurological diseases have an enormous market in China. We highly recognize NEULIVE MEDICAL's comprehensive layout in this field and are optimistic about the company’s dual capabilities in both passive interventional and active implantable technologies. We are also very pleased to collaborate with a top-tier domestic team like NEULIVE MEDICAL, which possesses product innovation, years of industry experience, and a global perspective."

Jiyuan Capital, founded in 2015, is an outstanding venture capital firm focused on the healthcare sector. By providing comprehensive value-added services and a global perspective, it empowers companies, drives innovation, and aims to bring long-term value to the development of the healthcare industry and human health. With an unwavering entrepreneurial spirit, we consistently uphold the values of "professionalism, humility, and diligence." Through long-term strategic partnerships, we assist and serve entrepreneurs, helping businesses establish themselves in China while embracing a global outlook, ultimately becoming great enterprises.

Chenzde Capital is an investment institution focused on innovative medical technology and cutting-edge biotechnology subfields. It is managed and operated by a professional team with a deep background in the medical industry and oversees multiple RMB funds and USD funds. Chenzde Capital adheres to the investment philosophy of "Focus, Excellence, and Reputation." Based on extensive industry resources and years of in-depth research and cultivation in the medical field, it promptly identifies the latest international technological trends and seizes investment opportunities driven by technological innovation. Chenzde Capital is committed to discovering top-tier enterprises with industry leadership potential and, through an interconnected and win-win investment methodology along with a precise and pragmatic post-investment empowerment system, collaborates with entrepreneurs to build an industrial ecosystem for mutual growth while delivering optimal returns to investors.